Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir (Runzhong) effectiveness and cost-effectiveness before versus after China's 4+7 procurement policy
ChiCTR1900023945Phase 4Not yet recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Entecavell in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Difference in efficacy and Drug economy. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
Entecavell
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1900023945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023945.